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Summary Purpose Amplification or over-expression of the
mitotic Aurora A kinase (AAK) has been reported in several
heme-lymphatic malignancies. MLN8237 (alisertib) is a novel
inhibitor of AAK that is being developed for the treatment of
advanced malignancies. The objectives of this phase I study
were to establish the safety, tolerability, and pharmacokinetic
profiles of escalating doses of MLN8237 in patients with
relapsed or refractory heme-lymphatic malignancies.Methods
Sequential cohorts of patients received MLN8237 orally as
either a powder-in-capsule (PIC) or enteric-coated tablet
(ECT) formulation. Patients received MLN8237 PIC 25–
90 mg for 14 or 21 consecutive days plus 14 or 7 days’ rest,
respectively, or MLN8237 ECT, at a starting dose of 40 mg/
day once-daily (QD) for 14 days plus 14 days’ rest, all in 28-
day cycles. Subsequent cohorts received MLN8237 ECT 30–
50 mg twice-daily (BID) for 7 days plus 14 days’ rest in 21-
day cycles. Results Fifty-eight patients were enrolled (PIC n =
28, ECT n =30). The most frequent grade ≥3 drug-related
toxicities were neutropenia (45 %), thrombocytopenia
(28%), anemia (19%), and leukopenia (19%). The maximum
tolerated dose on the ECT 7-day schedule was 50 mg BID.
The terminal half-life of MLN8237 was approximately 19 h.
Six (13 %) patients achieved partial responses and 13 (28 %)
stable disease.Conclusion The recommended phase II dose of
MLN8237 ECT is 50 mg BID for 7 days in 21-day cycles,
which is currently being evaluated as a single agent in phase
II/III trials in patients with peripheral T-cell lymphoma.
Keywords Phase I-III Leukemia and lymphomas . Novel
antitumor agent . Cell cycle mechanisms of anticancer drug
action . Aurora A kinase inhibitor .MLN8237
Introduction
The cell cycle is a tightly regulated process that allows faithful
inheritance of genetic material. Several kinase families includ-
ing the Aurora family of serine/threonine kinases meticulously
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control the mitotic phase of the cell cycle. In particular Aurora
A kinase (AAK) plays an essential role in chromosome align-
ment, centrosome separation and maturation, mitotic spindle
formation, and cytokinesis during mitosis [1–3].
Amplification or over-expression of AAK has been report-
ed in several heme-lymphatic malignancies [4–7], and Aurora
A may function as an oncogene through the induction of
genetic instability and enhanced survival signaling [8, 9];
increased Aurora A expression leads to enhanced cell survival
[9]. AAK has also been shown to inhibit the post mitotic
checkpoint by targeting p53 for degradation leading to inhi-
bition of p53-mediated apoptosis, and thereby bypassing cell
cycle arrest which in turn is associated with genomic instabil-
ity and oncogenic transformation [10, 11].
The fundamental role of AAK in cell cycle regulation and
its aberrant expression in a broad range of malignancies
prompted the development of agents that selectively inhibit
its activity. Early studies showed that targeted knockdown of
AAK led to accumulation of cells in the G2/M phase followed
by apoptosis and was associated with in vitro and in vivo
growth inhibition [12–14]. Inhibition of AAK expression has
also been shown to disrupt multiple events in mitosis, culmi-
nating in monopolar spindle formation, failure of centrosome
separation, and incomplete cytokinesis [3, 15].
MLN8237 (alisertib) is an investigational, orally active,
selective small molecule inhibitor of AAK that is being inves-
tigated for the treatment of both heme-lymphatic malignancies
and solid tumors [16]. MLN8237 inhibits AAK with an inhi-
bition constant (Ki) of 0.43 nM [17] and is approximately
200-fold more selective for AAK (IC50=6.7 nmol/L) than
Aurora B kinase (IC50=1,534 nM/L) in cell-based assays
[16]. Moreover, MLN8237 is selective for AAK over other
kinases (at least 250-fold more selective in vitro) and recep-
tors [15, 16, 18, 19]. In both preclinical [15, 18, 19] and
clinical studies [20, 21], MLN8237 has shown preliminary
antitumor activity in heme-lymphatic malignancies. Treat-
ment of multiple myeloma (MM) cells with MLN8237
in vitro resulted in mitotic spindle abnormalities, mitotic
accumulation, and apoptosis [15]. In a murine xenograft
MM model, tumor burden was significantly reduced (P=
0.007) and overall survival was significantly increased (P=
0.0044) in animals treated with MLN8237 [15]. Furthermore,
targeted inhibition of AAK with MLN8237 showed encourag-
ing antitumor activity in preclinical models of lymphoma [22].
MLN8237 has also been shown to inhibit tumor growth in
preclinical models of mantle cell lymphoma, the effect of which
was potentiated by docetaxel, and vincristine and rituximab [22,
23]. In two phase I studies in patients with solid tumors, a range
of doses and schedules were evaluated and the maximum toler-
ated dose (MTD) for MLN8237 was determined as 50 mg
twice-daily (BID) for 7-day schedule in 21-day cycles [17, 24].
This open-label, phase I study (NCT00697346) was per-
formed to determine the dose-limiting toxicities (DLTs) and
MTD, and to evaluate the safety, pharmacokinetics (PKs), and
preliminary antitumor activity of MLN8237 in patients with
advanced heme-lymphatic malignancies (MM, non-
Hodgkin’s lymphoma [NHL], and chronic lymphocytic leu-
kemia [CLL]). Various dosing schedules of two formulations
of MLN8237 were assessed in order to determine the optimal
strategy to use clinically.
Patients and methods
Patients
Eligible patients were aged ≥18 years and had: relapsed or
refractory heme-lymphatic malignancy who had failed stan-
dard regimens; Eastern Cooperative Oncology Group perfor-
mance status 0–2; radiographically or clinically evaluable
disease; absolute neutrophil count (ANC) ≥1,000/mm3 with-
out growth factor support; platelet count ≥50,000/mm3 with-
out transfusion requirement; creatinine clearance ≥30 mL/
min; total bilirubin ≤1.5 × upper limit of normal (ULN); and
aspartate/alanine aminotransferase ≤2.5 × ULN. Patients were
excluded if they had received: significant enzyme inducers,
enzyme-inducing antiepileptic drugs, or St John’s wort within
14 days; systemic antineoplastic therapy or antineoplastic
glucocorticoid treatment within 21 days; radiotherapy
(≥25 % of bone marrow) within 42 days; or radio-/toxin-
immunoconjugates within 56 days; prior allogeneic bone
marrow or other organ transplantation; proton pump inhibitors
starting 4 days prior to cycle 1. There was no restriction on the
number of prior therapies. Patients were also excluded if they
had known gastrointestinal disease that could interfere with
oral absorption of MLN8237, conditions that could result in
excessive daytime sleepiness, newly diagnosed or uncon-
trolled cancer-related central nervous system disease, or clin-
ically significant electrocardiogram abnormalities.
Study design and intervention
This open-label, phase I study was conducted at 9 centers in
the USA. The study was carried out in accordance with the
Declaration of Helsinki and GoodClinical Practice guidelines.
Institutional review boards and local independent ethics com-
mittees approved the study and all patients provided their
written informed consent for participation.
Patients received escalating doses of MLN8237 as either a
powder-in-capsule (PIC) or enteric-coated tablet (ECT) for-
mulation in a standard 3+3 design. Initially, only the PIC
formulation of MLN8237 was available; the protocol was
later modified to include assessment of the ECT formulation.
Dosing schedules are summarized in Supplementary Fig. S1
(online only). The PIC formulation starting dose was 25 or
35 mg/day. An initial loading dose was delivered BID on day
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1 of each cycle and patients subsequently received MLN8237
once daily (QD) on days 2–14 or 2–21, followed by 14 or
7 days’ rest, respectively, in 28-day cycles. For the ECT
formulation, the starting dose was 40 mg/day QD for 14 days
followed by 14 days’ rest in 28-day cycles. Subsequent co-
horts received MLN8237 ECT BID for 7 days followed by
14 days’ rest in 21-day cycles.
Escalation to the next dose level proceeded only if DLTs
were observed in 0/3 or 1/6 patients in cycle 1. If 2 of the first
3–6 patients experienced DLTs at a given dose level, dose
escalation was delayed while the available safety/clinical data
were assessed and a decision made on how to proceed with a
modified dose or schedule. In patients experiencing DLTs, the
next cycle of MLN8237 administration was delayed and
MLN8237 dose was reduced or discontinued accordingly at
the Investigator’s discretion. The use of myeloid growth fac-
tors (G-CSF or GM-CSF) or erythropoiesis-stimulating agents
was permitted after the DLT evaluation period was completed
(cycle 1) and on a case-by-case basis after cycle 2. Treatment
continued for up to 12 months, or until disease progression or
unacceptable toxicity, with the possibility of treatment exten-
sion beyond 12 months if clinical benefit was evident and
toxicities were manageable.
Endpoints
This study had two primary endpoints: to determine the DLTs
and MTD of orally administered MLN8237, and to estimate
PK parameters during cycle 1. PK parameters included: area
under the plasma concentration versus time curve, maximum
plasma concentration, time tomaximum plasma concentration
(Tmax), terminal half-life (t1/2), accumulation ratio (Rac), and
peak/trough ratio. Secondary endpoints were response rate,
duration of response, and evaluation of banked tumor tissue
samples for AAK protein expression and gene amplification.
Assessments
Safety
Adverse events (AEs) were graded by the National Cancer
Institute-Common Terminology Criteria for Adverse
Events v3.0 [25]. DLTs were defined as any of the fol-
lowing MLN8237-related AEs occurring during cycle 1:
grade 4 neutropenia (ANC <500/mm3) at any point during
dosing and lasting >7 days during the recovery period, or
with fever; grade 4 thrombocytopenia (platelet count <25,
000/mm3) at any point during dosing and lasting >7 days
during the recovery period; grade 3 thrombocytopenia with
clinically significant bleeding at any time; platelet count
<10,000/mm3 at any time; grade ≥3 nausea and/or emesis
despite optimal antiemetic prophylaxis; any other grade ≥3
nonhematologic toxicity, with the exception of grade 3
arthralgia/myalgia, any grade of alopecia, or brief
(<1 week) grade 3 fatigue; a required rest period of
>21 days due to an MLN8237-related toxicity; other grade
≥2 nonhematologic toxicities that, in the opinion of the
Investigator, required dose reduction or discontinuation of
therapy with MLN8237.
Response
Response was evaluated according to the International Work-
ing Group criteria for patients with lymphoma [26, 27], the
International Myeloma Working Group uniform response
criteria for patients with MM [28], and the International
Workshop on CLL guidelines [29].
Pharmacokinetics
MLN8237 plasma concentrations were measured using a
validated liquid chromatography/tandem mass spectrometry
assay. Plasma samples were collected in cycle 1 at various
time points on the first day (day 1) and last day (day 7, ECT 7-
day schedule; day 14, PIC or ECT 14-day schedules; day 21,
PIC 21-day schedule) of treatment. PK parameters were cal-
culated by non-compartmental analysis usingWinNonlin soft-
ware (v5.2.1, Pharsight Corporation, Cary, NC).
AAK protein expression and gene copy number determination
AAK protein and the phosphorylated Histone H3 (pHH3) at
serine 10 (Ser10) expression were determined from available
patient archived tumor samples using immunohistochemistry
(IHC). Aurora A gene and chromosome 20 copy number were
determined using fluorescent in situ hybridization (FISH).
IHC and FISH were carried out as described in Matulonis
UA, et al. 2012 [30].
Statistics
Sample size was driven by the dose-escalation scheme and
descriptive statistics were employed.
Results
Patients
A total of 58 patients were enrolled; 28 to MLN8237 PIC
dose levels and 30 to MLN8237 ECT. Patient demo-
graphics and baseline characteristics are summarized in
Table 1; median age was 61 years (range 27–82), 47 %
were male, and 90 % were white. The most common
tumor type was NHL (n =36, 62 %), of which the most
common subtypes were diffuse large B-cell lymphoma
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(DLBCL; n =16, 28 %) and follicular lymphoma (FL; n =
10, 17 %). Seventy-six percent (n =44) of patients had
received ≥3 prior lines of therapy (range 0–17).
Patients received a median of 2 treatment cycles (range 1–
15); 18 (31 %) patients completed ≥3 cycles, and 8 (14 %)
completed ≥6 cycles. Thirty-seven (64 %) patients
discontinued due to progressive disease. Treatment is ongoing
in 3 (5 %) patients (6, 15, 18 cycles).
DLTs and determination of MTD
DLTs by MLN8237 dose and schedule are listed in Table 2.
On the PIC 21-day QD schedule, 1/6 patients and 2/4 patients
in the 25 mg and 35 mg dose levels, respectively, experienced
DLTs, including grade 2/3 neutropenia and grade 3 thrombo-
cytopenia. On the PIC 14-day schedule, 0/3 patients who
received MLN8237 35 mg reported DLTs, and only 1/6 who
received 45 mg experienced a DLT of grade 3 thrombocyto-
penia resulting in treatment discontinuation. At 65 mg, 0/3
patients experienced a DLT and at 90 mg, 2/2 patients expe-
rienced a DLT. The dose was de-escalated to 65 mg and 4
additional patients were enrolled, 2 of whom experienced
DLTs (grade 4 neutropenia and grade 4 thrombocytopenia).
The MTD on the PIC 14-day schedule was determined to be
45 mg QD.
On the ECT 14-day QD schedule, 2/6 patients who re-
ceived MLN8237 40 mg experienced DLTs (1 patient with
grade 4 febrile neutropenia; 1 with grade 4 bullous dermatitis
and grade 4 neutropenia), and further dose escalation on this
schedule was abandoned. On the ECT 7-day BID schedule, no
DLTs were reported in the 30 mg and 40 mg cohorts; 1/10
patients in the 50 mg cohort experienced a DLT of grade 4
neutropenia. The MTD on the ECT 7-day BID schedule was
therefore determined as 50 mg BID (ie. 100 mg total dose per
day).
Safety
All 58 patients were included in the safety population. The
safety profile for both MLN8237 formulations is summarized
in Supplementary Table S1 (online-only). All patients experi-
enced at least 1 treatment-emergent AE, and 90 % reported
drug-related AEs. Common all-grade and grade ≥3 drug-
related AEs are summarized in Table 3. In total, 35 (60 %)
patients (PIC n =14, ECT n =21) reported grade ≥3 drug-
related AEs, the most common of which were neutropenia
(45 %), and thrombocytopenia (28 %). While frequencies of
myelotoxicity somewhat differed between patient groups en-
rolled to the ECT versus PIC formulations (Table 3), quanti-
tative comparisons are confounded by both the different doses
Table 1 Patient demographics
and baseline characteristics
ASCT autologous stem-cell trans-
plant; EBV Epstein–Barr virus;
ECOG Eastern Cooperative On-
cology Group; ECT enteric-coat-
ed tablet; NHL non-Hodgkin
lymphoma; PIC powder-in-
capsule
a Other types of NHL (each n =1)
were: angio-immunoblastic T-cell
lymphoma; nodal marginal zone
B-cell lymphoma; EBV-positive
T-cell lymphoma; marginal zone
B-cell lymphoma transforming to
diffuse large B-cell lymphoma;
natural killer/T-cell lymphoma,
nasal type; and small cell lympho-
ma/follicular lymphoma
bBoth patients had noncutaneous
peripheral T-cell lymphoma—not
otherwise specified
MLN8237 PIC MLN8237 ECT Total
n =28 n =30 N =58
Median age, years (range) 62 (41–74) 57 (27–82) 61 (27–82)
Male, n (%) 14 (50) 13 (43) 27 (47)
Race
White 24 (86) 28 (93) 52 (90)
Black or African American 3 (11) 1 (3) 4 (7)
Asian 0 1 (3) 1 (2)
Not reported 0 1 (3) 1 (2)
Tumor type, n (%)
Non-Hodgkin lymphomaa 18 (64) 18 (60) 36 (62)
Diffuse large B-cell lymphoma 9 (32) 7 (23) 16 (28)
Follicular lymphoma 5 (18) 5 (17) 10 (17)
Mantle-cell lymphoma 2 (7) 0 2 (3)
Peripheral T-cell lymphoma 0 2 (7)b 2 (3)
Multiple myeloma 8 (29) 11 (37) 19 (33)
Chronic lymphocytic leukemia/
small lymphocytic leukemia
2 (7) 1 (3) 3 (5)
ECOG performance status
0/1/2, n (%)
5 (18)/17 (61)/6 (21) 8 (27)/16 (53)/6 (20) 13 (22)/33 (57)/12 (21)
Prior therapy, n (%)
Radiation therapy 11 (39) 14 (47) 25 (43)
ASCT 12 (43) 11 (37) 23 (40)
≥3 prior systemic therapies, n (%) 22 (79) 22 (73) 44 (76)
Primary refractory disease 8 (36) 12 (43) 22 (39)
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and schedules administered with the two formulations, and
potential effects of differing baseline marrow reserves. For
example, most patients received the ECT formulation BID for
7 days whereas those receiving MLN8237 PIC received it
BID on day 1 only and QD thereafter. The effect of a higher
total dose of MLN8237 over a shorter time period probably
accounts for the higher rates of neutropenia and thrombocy-
topenia in the ECT group.
Twenty-eight (48 %) patients (PIC n =12, ECT n =16)
experienced serious AEs, the most common of which was
febrile neutropenia (PIC n =1, ECT n =4). In total, 9 (16 %)
patients (PIC n =4, ECT n =5) discontinued treatment due to
Table 3 Most frequent drug-related AEs in ≥10 % (any grade) or ≥5 % (grade ≥3) of patients in the overall population
AE, n (%) MLN8237 PIC MLN8237 ECT MLN837 ECT at MTD* Total
n =28 n=30 n =10 N =58
All grades Grade ≥3 All grades Grade ≥3 All grades Grade 3 Grade 4 All grades Grade ≥3
Neutropenia 13 (46) 10 (36) 20 (67) 16 (53) 7 (70) 3 (30) 2 (20) 33 (57) 26 (45)
Thrombocytopenia 11 (39) 8 (29) 13 (43) 8 (27) 5 (50) – 2 (20) 24 (41) 16 (28)
Diarrhea 8 (29) – 12 (40) 1 (3) 4 (40) – – 20 (34) 1 (2)
Anemia 8 (29) 4 (14) 11 (37) 7 (23) 4 (40) 2 (20) 1 (10) 19 (33) 11 (19)
Fatigue 9 (32) 2 (7) 6 (20) – 1 (10) – – 15 (26) 2 (3)
Vomiting 6 (21) – 2 (7) – – – – 8 (14) –
Alopecia 4 (14) – 11 (37) – 4 (40) – – 15 (26) –
Leukopenia 3 (11) 2 (7) 10 (33) 9 (30) 4 (40) 2 (20) 2 (20) 13 (22) 11 (19)
Nausea 9 (32) – 3 (10) – – – – 12 (21) –
Lymphopenia 2 (7) – 6 (20) 4 (13) 2 (20) 1 (10) 1(10) 8 (14) 4 (7)
Stomatitis 2 (7) 1 (4) 5 (17) – 1 (10) – – 7 (12) 1 (2)
Somnolence 1 (4) – 5 (17) – 2 (20) – – 6 (10) –
Decreased WBC count 1 (4) 1 (4) 4 (13) 2 (7) 2 (20) 2 (20) – 5 (9) 3 (5)
Febrile neutropenia 1 (4) 1 (4) 4 (13) 4 (13) 2 (20) 1 (10) 1 (10) 5 (9) 5 (9)
*MTD, 50 mg BID
AE adverse event; ECT enteric-coated tablet; MTD maximum tolerated dose; PIC powder-in-capsule; WBC white blood cell
Table 2 DLTs reported in
patients receiving MLN8237
treatment
BID twice daily; DLT dose-lim-
iting toxicity; ECT enteric-coated
tablet; PIC powder-in-capsule;
QD once daily
Schedule Dose level N Patients with DLT, n Description of DLTs observed in each patient
PIC 21-day 25 mg QD 6 1 Grade 2 neutropenia, grade 3 thrombocytopenia,
grade 3 neutropenia
35 mg QD 4 2 Grade 3 neutropenia, grade 3 thrombocytopenia
resulting in treatment discontinuation
Grade 3 neutropenia resulting in treatment
discontinuation
PIC 14-day 35 mg QD 3 –
45 mg QD 6 1 Grade 3 thrombocytopenia resulting in treatment
discontinuation
65 mg QD 7 2 Grade 4 thrombocytopenia
Grade 4 neutropenia
90 mg QD 2 2 Grade 3 febrile neutropenia
Grade 4 thrombocytopenia
ECT 14-day 40 mg QD 6 2 Grade 4 febrile neutropenia
Grade 4 bullous dermatitis resulting in treatment
discontinuation, grade 4 neutropenia
ECT 7-day 30 mg BID 3 –
40 mg BID 9 –
50 mg BID 10 1 Grade 4 neutropenia
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AEs of which thrombocytopenia (n =4), neutropenia, bullous
dermatitis (n =1), and confusion (n =1) were drug-related.
There were 6 (10 %) on-study deaths (deaths occurring
during treatment or within 30 days of last dose); none of which
were considered treatment-related. In the PIC population, the
3 reported deaths were due to renal failure, an acute exacer-
bation of obstructive airways disorder, and progressive lym-
phoma. In the ECT population, the 3 reported deaths were due
to progressive MM (n =2) and hypercalcemia in a patient with
DLBCL.
Pharmacokinetics
Mean plasma concentration–time profiles for MLN8237 ECT
BID on days 1 and 7, are shown in Fig. 1. The summary
statistics of PK parameters for this dosing regimen are pre-
sented in Supplementary Table S2 (online only).
An integrated assessment of the PK parameters was per-
formed across dose cohorts in all 58 patients who received
either the PIC or ECT formulation of MLN8237. The validity
of this assessment was supported by the lack of a readily
apparent nonlinearities in the PK of MLN8237 and the lack
of a readily apparent effect of formulation on overall mean
apparent oral clearance (CLss/F; mean CLss/F; 4.5 and 5 L/h
for MLN8237 PIC or ECT, respectively). MLN8237 absorp-
tion was rapid, with an overall median Tmax of 2 and 2.6 h
following oral administration of MLN8237 PIC or ECT, re-
spectively. The overall mean steady-state t1/2 following
multiple-dose administration was approximately 19 h (range:
10–43 h). The Rac ratio was 2.5 for BID dosing (coefficient of
variation [CV %]: 35 %, n =18). Mean CLss/F was 4.8 L/h
(CV %: 69 %, n =42).
Antitumor activity
Forty-seven patients were response-evaluable; 6 patients had a
partial response (PR) and 13 had stable disease (SD) for 1.9–
11.0 months (Fig. 2). Scans for a heavily pre-treated patient
with relapsed DLBCL who achieved PR are shown in Fig. 3,
along with additional details regarding all 6 patients with PR.
Aurora A protein expression and gene copy number
AAK and pHH3(Ser10) (used as a marker for the incidence of
mitotic cells) protein expression were determined by IHC using
available archived tumor biopsies (n =22) collected from pa-
tients prior to enrollment in this study (Fig. 4a and b). Of these,
3 response-evaluable patients showed a marked increase in
AAK protein levels; 2 of these patients (1 with peripheral T-
cell lymphoma- not otherwise specified [PTCL-NOS] and the
other with FL) had a PR as best response and the third patient
(with EBV-positive T-cell lymphoma), experienced progressive
disease. These patients showed variable incidence of mitotic
cells (based on pHH3(Ser10) expression levels) and there was
no apparent correlation with clinical response (Fig. 4b). Aurora
A gene and chromosome 20 copy numbers were evaluated by
FISH in 11 response-evaluable patients. In 2 of these patients, 1
with T-cell lymphoma and the other with angioimmunoblastic
T-cell lymphoma, the analyzed tumors showed an increase in
Aurora A gene copy number (Fig. 4c). Interestingly tumor
samples from the patient with T-cell lymphoma also showed
an increase in Aurora A protein levels. In all analyzed samples
the Aurora A /chromosome 20 ratio was close to 1, suggesting
that the increased Aurora A gene copy number in the 2 patients
was due to amplification of chromosome 20 (Fig. 4d).
Discussion
This was the first phase I study to evaluate the safety and PKs
of the investigational AAK inhibitor MLN8237 as PIC or
ECT formulations in patients with advanced heme-lymphatic
malignancies. Previous studies have shown that doses of
Fig. 1 Mean plasma
concentration–time profiles of
MLN8237 (ECT formulation, 7-
day BID schedule) on days 1 and
7 (first dose). BID twice daily;
ECT enteric-coated tablet
Fig. 2 MLN8237 exposure and response in a all response-evaluable
patients and b all response-evaluable patients with lymphomas. Largest
percent change in target lesions in patients with lymphoma is shown in
panel c . AITL angioimmunoblastic T-cell Lymphoma; CLL chronic
lymphocytic leukemia; DLBCL diffuse large B-cell lymphoma; EBV-
TCL Epstein–Barr virus-T cell lymphoma; FL follicular lymphoma;
MCL mantle cell lymphoma; MM multiple myeloma; MZL marginal
zone B-cell lymphoma; NK/TCL natural killer/T-cell lymphoma; PD
progressive disease; PR partial response; PTCL-NOS peripheral T-cell
lymphoma- not otherwise specified; SCL small cell lymphoma; SLL
small lymphocytic leukemia
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MLN8237 25–70 mg for 21 days were associated with pre-
dominantly hematologic DLTs [17, 24, 31]. On the other hand,
higher daily doses administered over shorter treatment periods
such as 7 days have been shown to be generally tolerable [17,
24]. The MTD of single-agent MLN8237 in this patient popu-
lation with heme-lymphatic malignancies was 45 mg QD on a
14-day schedule for the PIC formulation and 50mgBID on a 7-
day schedule for the ECT formulation. The same MTD for the
7-day BID schedule was defined in two previous phase I studies
of MLN8237 PIC [17, 24] and ECT [17] in patients with
advanced solid tumors. The ECT formulation has been chosen
for future development as it allows MLN8237 (an acidic drug
with low aqueous solubility) to bypass stomach acid (gastric
pH, 1–4) and delays dissolution until delivery to the small
intestine [16, 17].
In the present study, MLN8237 was generally well tolerat-
ed. Common side effects included hematologic AEs, gastro-
intestinal AEs, and alopecia. In general, significant cumulative
toxicities were not observed, and the most frequently occur-
ring toxicities were generally reversible in the recovery period
between cycles. Although grade 3 or higher neutropenia was
reported with high frequency (45 %) across all cohorts, the
frequency of grade 3 or higher febrile neutropenia was 9 %.
Grade 4 neutropenia was only seen in 1/10 patients treated at
the MTD dose of 50 mg BID for the ECT formulation.
The PK properties of MLN8237 in patients with heme-
lymphatic malignancies were generally consistent with those
observed in a previous study of patients with advanced solid
tumors [17]. Based on the integrated PK assessment across
dose cohorts in all 58 patients, the range of apparent oral
clearance of MLN8237 observed following administration as
the ECT formulation was comparable to that observed follow-
ing administration as PIC, supporting the conclusion of
achievement of similar systemic exposures following admin-
istration as either the ECT or PIC formulation. This observa-
tion is also consistent with results from the bioavailability part
of the study, which showed that the bioavailabilities of
MLN8237 PIC and ECTwere similar [17].
Increased levels of Aurora A protein were observed in 3
response evaluable patients among 22 available archived tu-
mor biopsies. Of note, 2 of these patients had PRs whereas 1
patient experienced progressive disease. In addition, 2 patients
had amplified Aurora A gene copy number. Aurora A ampli-
fication in these tumors was most likely due to increased
chromosome 20 copy number as the Aurora A /chromosome
20 ratio was close to 1.
Fig. 3 Antitumor activity in a
patient with diffuse large B-cell
lymphoma receiving 65 mg
MLN8237 PIC QD 14-day (Top).
Tumor type, MLN8237 treatment
regimen and additional details for
all 6 patients who achieved a PR
(Bottom). BEAM carmustine,
etoposide, cytarabine, melphalan;
BID twice daily; ECT enteric
coated tablet; PIC powder-in-
capsule; PR partial response; QD
once daily
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Aurora A protein overexpression and gene amplification
have been linked to the etiology of a variety of cancers,
including heme-lymphatic malignancies [4–7]. The number
of response evaluable patients with available and informative
archived tumor samples was too small to determine if there
was a correlation between Aurora A protein expression and
gene copy number with MLN8237 response. Identifying bio-
markers predictive of response to Aurora kinase inhibitors has
been challenging and larger studies will be needed to deter-
mine if tumor Aurora A expression or gene amplification
correlates with response [32].
MLN8237 has also shown potential antitumor activity in a
recent phase II study of single-agent MLN8237 (50 mg BID)
in patients with aggressive B- and T-cell NHL [20]. The
overall response rate in all 48 treated patients was 27 %
(10 % CR and 17 % PR), with 33 % of patients achieving
SD. Of particular note, 4/8 patients with T-cell lymphoma had
a response [20]. While not a primary focus of the study, the
preliminary antitumor activity seen here warrants further
investigation. MLN8237 showed signs of antitumor activity
as a single agent in patients with advanced heme-lymphatic
malignancies including MM, DLBCL, FL, and PTCL. Six
(13 %) patients (2 with FL, 1 each with DLBCL, marginal
zone B-cell lymphoma transformed to DLBCL, MM, and
PTCL) who had each received several prior therapies achieved
a PR, and 13 (28 %) achieved SD.
Taken together, these results support further evaluation of
the safety and antitumor activity of MLN8237 in NHL and
MM in appropriately designed clinical studies. Based on the
results of this study and an initial phase II study of MLN8237
in patients with lymphoma [20], a phase II (SWOG S1108;
NCT01466881—accrual complete) and a randomized phase
III trial of single-agent MLN8237 compared with investiga-
tor’s choice of pralatrexate, romidepsin, or gemcitabine in
relapsed or refractory PTCL (NCT01482962) is now under-
way. The rationale for evaluating the clinical activity of
MLN8237 in T-cell lymphomas is further supported by recent
preclinical studies showing that both AAK and Aurora B
Fig. 4 Aurora A and pHH3(Ser10) expression and Aurora A gene copy
number inavailable archived tumors. IHC analysis of Aurora A protein
expression in a PTCL-NOS sample (a). Percentage of cells positive for
Aurora A and pHH3 revealed by IHC (b). FISH analysis of Aurora A
gene copy number (c). Ratio of Aurora A gene copy number relative to
chromosome 20 gene copy number (d). FISH fluorescent in situ hybrid-
ization; IHC immunohistochemistry; pHH3(Ser10) phosphorylated His-
toneH3 at serine 10; PD progressive disease; PR partial response; PTCL-
NOS peripheral T-cell lymphoma- not otherwise specified; SD stable
disease
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kinase are expressed in T-cell lymphoma cell lines [33] and in
patient samples from the SWOG S0350 study [34], and that
MLN8237 induces endo-reduplication and apoptosis in PTCL
cell lines [33]. In addition, based on evidence that MLN8237
combined synergistically with rituximab and vincristine in
preclinical models of lymphoma [22], a phase I/II trial of
MLN8237 in combination with rituximab and vincristine in
patients with relapsed or refractory aggressive B-cell lympho-
ma is also underway (NCT01397825).
In conclusion, the recommended phase II dose for
MLN8237 is 50 mg BID for 7 days followed by a 14-day
recovery period, in 21-day cycles. MLN8237 was generally
tolerated in these patients with advanced heme-lymphatic
malignancies. Preliminary antitumor activity was observed
in patients with refractory NHL and MM. MLN8237 con-
tinues to be evaluated as a single agent and in combination
with other agents in relapsed or refractory NHL.
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